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Doxorubicin (DOX) is an antitumour agent for different types of cancer, but the dose-related cardiotoxicity limits its clinical use. To
prevent this side effect we have developed the flavonoid monohydroxyethylrutoside (monoHER), a promising protective agent,
which did not interfere with the antitumour activity of DOX. To obtain more insight in the mechanism underlying the selective
protective effects of monoHER, we investigated whether monoHER (1mM) affects DOX-induced apoptosis in neonatal rat cardiac
myocytes (NeRCaMs), human endothelial cells (HUVECs) and the ovarian cancer cell lines A2780 and OVCAR-3. DOX-induced cell
death was effectively reduced by monoHER in heart, endothelial and A2780 cells. OVCAR-3 cells were highly resistant to DOX-
induced apoptosis. Experiments with the caspase-inhibitor zVAD-fmk showed that DOX-induced apoptosis was caspase-dependent
in HUVECs and A2780 cells, whereas caspase-independent mechanisms seem to be important in NeRCaMs. MonoHER suppressed
DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and
activation of caspase-9 and -3 cleavage. Thus, monoHER acts by suppressing the activation of molecular mechanisms that mediate
either caspase-dependent or -independent cell death. In light of the current work and our previous studies, the use of clinically
achievable concentrations of monoHER has no influence on the antitumour activity of DOX whereas higher concentrations as used
in the present study could influence the antitumour activity of DOX.
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Doxorubicin (DOX) is highly effective against various types of
cancers, including leukaemias, breast and ovarian cancer. Doxo-
rubicin (DOX) induces pleiotropic cytotoxic effects of which
DNA intercalation and topoisomerase II inhibition have been
proposed to play an important role in its mechanism of action,
causing growth arrest and the subsequent activation of apoptosis
(Capranico et al, 1990; Gewirtz, 1991; Binaschi et al, 1997).
The contribution of DOX-induced reactive oxygen species (ROS)
to its antitumour activity is still a matter of debate (Keizer
et al, 1991; Shacter et al, 2000; Gouaze et al, 2001; Suresh et al,
2003).
A major limitation of the use of DOX in the clinic is its
cumulative dose-related cardiotoxicity, which ultimately can lead
to severe and irreversible forms of cardiomyopathy (Lefrak et al,
1973; Singal and Iliskovic, 1998; Hrdina et al, 2000). Doxorubicin
(DOX)-induced ROS have been shown as the primary cause of the
heart damaging effect of the drug (Horenstein et al, 2000; Xu et al,
2001). In addition, several studies suggested that DOX-induced
apoptosis in endothelial cells and cardiomyocytes contributes to
the development of DOX-related cardiotoxicity (Childs et al, 2002;
Wu et al, 2002; Kluza et al, 2004; Spallarossa et al, 2004). Various
strategies have been developed to protect against DOX-induced
cardiotoxic effects. The majority of these studies concern either
metal ion chelators or antioxidants that yielded moderate
protective effects (Swain et al, 1997; Kotamraju et al, 2000; Liu
et al, 2002; Yamanaka et al, 2003; Oliveira et al, 2004).
MonoHER — a semisynthetic flavonoid that was developed in
our laboratory (Willems et al, 2006) and presently in a phase II
clinical trial is both a radical scavenging and a metal ion
chelating agent (Haenen et al, 1993; van Acker et al, 1993). In
our studies the scavenging activity of monoHER was measured
by determining the inhibition of ferricytochrome c reduction and
the inhibition of oxygen consumption, showing an inhibition of 91
and 70%, respectively (van Acker et al, 1993). Because of these
favourable properties, monoHER was tested as a protectant against
DOX-induced cardiac damage in in vivo models and appeared a
potent protector against DOX-induced cardiotoxicity without
influencing its antitumour effects (van Acker et al, 1997, 2000).
The present study was initiated to determine possible differ-
ences in the effects of monoHER against DOX-induced apoptosis
in cardiac myocytes and vascular endothelial cells in comparison
to ovarian cancer cell lines. The protective effects of monoHER on
cell cycle progression and molecular determinants of mitochon-
drial-dependent apoptosis were also studied. The clinical relevance
of our results regarding the use of protectors such as monoHER in
combination with chemotherapy is discussed. Revised 14 December 2006; accepted 19 December 2006
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Chemicals
7-Monohydroxyethylrutoside (monoHER) was kindly provided
by Novartis Consumer Health (Nyon, Switzerland). Doxorubicin
HCl was purchased from Pharmacia Upjohn BV (Woerden, the
Netherlands). The following reagents were used in this study:
bovine serum albumin, trypsin, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and sodium vanadate
(NaVO3) (all from Sigma-Aldrich Chemie (Zwijndrecht, the
Netherlands)); human serum (Central Laboratory for Blood
Transfusion, Amsterdam, the Netherlands); M199 medium and
Hanks Balanced salt solution (without calcium) (Invitrogen, Breda,
the Netherlands); Dulbecco’s modified Eagle’s medium (DMEM)
and HEPES (Cambrex Bio Science, New Jersey, USA); fetal
calf serum (FCS) (Greiner Bio-One B.V., Alphen a/d Rijn,
the Netherlands); Na-penicillin-G (Yamanouchi Pharma B.V., the
Netherlands); streptomycin (Fisiopharma, Milano, Italy); L-gluta-
mine (ICN Biochemicals, Cleveland, Ohio, USA); horse serum (Life
Technologies NV, Merelbeke, Belgium); glycerol (J.T. Baker,
Europe, Deventer, the Netherlands); protease inhibitor tablets
(Roche Diagnostics Netherland BV, Almere, the Netherlands);
Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl keton (z-VAD)
(Enzyme Systems, Livermore, CA, USA); Endothelial cell growth
factor (ECGF) was extracted from bovine hypothalamus as
described previously (Maciag et al, 1979).
Cell culture
All cells were maintained at 371C in humidified air containing 5%
CO2. A2780 and OVCAR-3 cells were grown in DMEM with
10% FCS and 20mM HEPES. Human endothelial cells (HUVECs)
were prepared as described previously by Verheul et al (2000). In
brief, the endothelial cells were cultured in gelatin-coated
(1%) tissue culture plates with culture medium consisting of
M199 supplemented with 10% human serum, 10% FCS, 5Uml
1
heparin, 200IEml
1 penicillin and 200mgml
1 streptomycin,
0.29mgml
1 L-glutamine and 50mgml
1 ECGF. Cells were grown
to confluence at 371Ci n5 %C O 2. Endothelial cells after three
passages (P3) were used during the whole study. Neonatal rat
cardiac myocytes (NeRCaMs) were isolated as described pre-
viously by (Abou El Hassan et al, 2003a). The cardiac cells were
divided over tissue culture plates with a cell density of
7510
3cellscm
2. After plating, the cells were incubated with
medium consisting of equal portions of DMEM and Ham’s F-10
supplemented with 100Uml
1 penicillin, 100mgml
1 streptomycin
and 5% horse serum. The cultures contained at least 90% of
synchronously beating NeRCaMs. After 24h the medium was
refreshed and 48h later the NeRCaM cultures were ready for use in
the experiments.
Flow cytometric analysis of PI-stained cells
Cardiac myocytes, endothelial, A2780 and OVCAR-3 cells were
treated with different concentrations of DOX (0.1–10mM) alone or
in the presence of 1mM monoHER for 48h, respectively. Apoptotic
cell fraction (sub-G1) in PI-stained cells was measured by flow
cytometry as described previously (Swain et al, 1997; Suresh et al,
2003). In brief, after trypsinisation the cells were resuspended in
PI staining solution (50mMml
1 PI, 0.1% sodium citrate, 0.1%
TritonX-100, 0.1mgml
1 Rnase in PBS). The cells were incubated
for at least 30min at 41C in the dark before analysis by flow
cytometry using a FACScan (Becton, Dickinson and Company, NJ,
USA). When indicated cells were pretreated for 1h with 50mM of
the broad caspase inhibitor z-VAD-fmk before DOX exposure or
co-treated with monoHER (1mM).
Western blot analysis
Cells were treated with DOX with or without 1mM MonoHER for
24 and 48h at 371C. The cells were trypsinised and lysed for 20min
on ice in lysis buffer consisting of 20mM HEPES/KOH (pH 7.4),
50mMb-glycerophosphate, 50mMKCl, 0.2mM EDTA, 1% (w/v)
Triton X-100, and 10% (w/v) glycerol, supplemented with protease
inhibitors and 1mMNaVO3. Protein concentrations were deter-
mined using the Bio-Rad assay (Bio-Rad Laboratories, Richmond,
CA, USA) with BSA as a standard using a spectrophotometer.
Equal amounts of protein (15mg) were loaded and electrophoresed
on 7–12% SDS–polyacrylamide gels and transferred into poly-
vinylidene difluoride membranes (Amersham, Braunschweig,
Germany). Subsequently, membranes were blocked with 5% non-
fat dry milk for 1h at room temperature and incubated at 41C
overnight with the indicated primary antibodies followed by a 1h
incubation at room temperature with a secondary antibody, either
horseradish peroxidase-conjugated goat anti-mouse or goat anti-
rabbit antibodies (1:2000). Protein loading equivalence was
assessed by the expression of b-actin (1:10000). Proteins were
visualised by enhanced chemiluminescence (ECL kit, Amersham,
Braunschweig, Germany). Primary antibodies used were against
p53 (human specific, DAKO, Glostrup, Denmark), poly(ADP-
ribose) polymerase (PARP) (Roche Diagnostics Netherland BV,
Almere, the Netherlands), caspase-9 (human specific or mouse
mAb), p53 and PARP (rat specific, all from Cell Signaling
Technology Inc., Beverly, MA, USA), Bax and caspase-3 (BD
Transduction Laboratories NJ, USA) and b-actin (Sigma-Aldrich
Chemie, Zwijndrecht, the Netherlands).
RESULTS
Effect of monoHER on DOX-induced apoptosis
Normal cells were more sensitive to DOX-induced apoptosis than
the selected tumour cell lines. The IC50 values were 0.75, 0.5 and
1.5mM for HUVECS, NeRCaMs and A2780 cells, respectively.
However, OVCAR-3 was highly resistant with a maximum of only
10–12% cells in sub-G1 phase at 10mM (Figure 1 and Table 1).
HUVECs were relatively resistant to low concentrations of DOX
and reached a plateau of apoptotic cell fraction at a concentration
of 1mM. NeRCaMs displayed a gradual dose-dependent increase of
apoptotic cells at low DOX concentrations reaching a plateau of
60% killing at 1mM DOX. A2780 cells also showed a dose-
dependent increase in apoptotic cells, reaching a plateau of about
50% at DOX concentrations X1mM. The ratios of the IC50 values
shown in Table 1 indicate that 1mM MonoHER protected 13- and
15-fold against DOX-induced apoptosis in HUVECs and NeRCaMs,
respectively. A2780 cells were only protected with a factor 5.3,
whereas OVCAR-3 did not show any protection by monoHER.
Doxorubicin-induced caspase activation
The differences found in sensitivity to the apoptotic effects of DOX
in the examined cell panel prompted us to investigate the role of
caspases in mediating cell death. To that purpose, HUVECs,
NeRCaMs, A2780 and OVCAR-3 cells were treated with 1mM DOX
with or without the addition of the broad-spectrum caspase
inhibitor z-VAD-fmk (Figure 1C). A strong suppression (leaving
only 15% apoptotic cells) was observed in HUVECs whereas no
significant protection was observed in NeRCaMs. In tumour cells,
z-VAD-fmk almost completely protected against the moderate
apoptotic effects of DOX in A2780 cells (only 10% apoptotic cells
left). Z-VAD-fmk exhibited no significant protection against DOX-
induced apoptotic effects in OVCAR-3; however the interpretation
of this finding is difficult in light of the strong apoptosis resistance
found in these cells. Taken together, these results indicate that
DOX-induced apoptosis in HUVECs and A2780 cells was
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3 cells displayed less or hardly any contribution of caspases to
DOX toxicity. In addition, the effect of a higher dose of DOX
(10mM) with or without the addition of z-VAD-fmk was examined
inducing a more robust cell death than 1mM DOX. Under these
conditions, z-VAD-fmk showed comparable results as obtained at
1mM DOX (results not shown).
Cell cycle effects of DOX treatment
The effect of the combined treatment of DOX (1mM, 48h) with
monoHER or z-VAD-fmk on cell cycle progression in the panel of
non-tumour and tumour cells was determined by FACS analysis
of PI-stained cells (Figure 2). Doxorubicin (DOX) alone induced
apoptosis as illustrated by the accumulation of cells in sub-G1.
HUVECs were most sensitive to DOX and monoHER-dependent
suppression of DOX-induced sub-G1 accumulation was clearly
accompanied by G2/M arrest. The cell cycle profile obtained
after caspase inhibition displayed accumulation of HUVECs in
all cell cycle phases with a distribution resembling that of
untreated control cells. In NeRCaMs co-exposure with monoHER
protected against apoptosis, and a small increase in G2/M
accumulation was observed. A2780 tumour cells showed strong
accumulation in G2/M upon apoptosis suppression by co-
treatment with monoHER; z-VAD-fmk also led to G2/M accumula-
tion and strong S-phase arrest. In apoptosis-resistant OVCAR-3
cells DOX mediated an S-phase arrest that was strongly prevented
by monoHER, leading to a large accumulation in G2/M. Co-
treatment with z-VAD-fmk resulted in accumulation of cells in the
G2/M phase.
Taken together, it appears that monoHER delays DOX-treated
cells in the G2/M phase, particularly in the examined tumour cells.
Caspase inhibition by z-VAD-fmk was most notable in HUVECs
where DOX apoptotic effects seem to be merely caspase-
dependent, whereas other cell types showed partial inhibition or
in case of OVCAR-3 almost no effect at all. Although both
monoHER and z-VAD-fmk had overlapping effects on the cell
cycle distribution of DOX-treated cells, mainly G2/M accumula-
tion, z-VAD-fmk resulted also in the delay of the tumour cells in
the S phase, and in the G1 phase in case of HUVECs or NeRCaMs.
Because monoHER can suppress DOX cytotoxicity in all these cells
it apparently suppresses both caspase-dependent and -indepen-
dent forms of cell death.
Effect of monoHER on DOX-dependent activation of p53,
Bax and caspases
To obtain more insight into the molecular mechanism underlying
the apoptosis-inducing effect of DOX and the apoptosis suppres-
sing effects of monoHER, the expression of several regulators and
executors of apoptosis was studied in the panel of cells by Western
blotting. To that purpose, cells were exposed to the corresponding
IC50 concentrations of DOX in the presence or absence of
monoHER for 24 and 48h.
In HUVECs (Figure 3A), DOX treatment resulted in an
accumulation of p53 at 24h exposure which decreased at 48
post-treatment, most probably caused by the strong activation of
apoptosis resulting in the degradation of cellular proteins. This
finding was supported by a decrease in b-actin levels. Interestingly,
co-exposure with monoHER suppressed p53 accumulation. A
small increase in p53 levels may be observed after 24h treatment
with monoHER alone, which was not detected after 48h. This
increase was not seen in the other cells tested (see below).
Although we have no clear explanation for this small increase it
may reflect a more ROS-sensitive regulation of p53 in untreated
HUVECs than in the other cells.
The pro-apoptotic Bcl2 family member Bax was constitutively
expressed in untreated HUVECs and a shorter form of Bax of
approximately 18kDa appeared after treatment with DOX
probably representing a cleaved or truncated form. The occurrence
of this shorter variant was, however, prevented by monoHER. As
predicted by the z-VAD-fmk sensitivity of DOX-induced apoptosis
in these cells, robust caspase-9 and -3 cleavage was seen
accompanied by processing of the caspase substrate PARP.
MonoHER suppresses caspase activation. As controls, DMSO and
monoHER alone did not trigger caspase activation.
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Figure 1 The effect of monoHER (1mM) on DOX-induced apoptosis in
cardiomyocytes (NeRCaMs), endothelial cells (HUVECs) (A) and ovarian
tumour cells A2780 and OVCAR-3 (B) after 48h of incubation. The bars
indicate the levels of the sub-G1 cell fractions of apoptotic cells after PI
staining. The effect of 50mM zVAD-fmk (a broad-spectrum caspase
inhibitor) on DOX (1mM, 48h)-induced cell death was also investigated
(C). Results are presented as the mean (7s.d.) of three independent
experiments except for the NeRCaMs in Figure 1A, where results of two
experiments are shown.
Table 1 IC50 values (mM) for endothelial (HUVECs), cardiac cells
(NeRCaMs), OVCAR-3 and A2780 cells
Cell type DOX DOX+MH Fold protection
HUVECs 0.75 10 13
NeRCaMs 0.5 7.5 15
A2780 1.5 8 5.3
OVCAR-3 410 410 —
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Figure 2 Effect of 1mM monoHER and 50mM zVAD-fmk on cell cycle progression in cardiomyocytes, endothelial cells and ovarian cancer cells treated
with 1mM DOX for 48h. The percentage of cells in the different cell cycle fractions was determined by flow cytometry.
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Figure 3 Effect of monoHER on DOX-induced p53, Bax and caspase activation. The expression of the indicated proteins was examined by Western
blotting in HUVECs (A), NeRCaMs (B), and in A2780 (C) and OVCAR-3 tumour cells (D) after 24 and 48h of DOX exposure at their IC50. The molecular
weight of the bands is indicated and b-actin was included as a control for protein loading.
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treatment and monoHER appeared to influence the post-transla-
tional modification of p53 as indicated by changes in the mobility
of the p53 specific bands (Figure 3B). Doxorubicin (DOX) potently
triggered caspase-9 activation as indicated by the strong decrease
or even absence of the pro-form band at 24 and 48h after
treatment. Also strong PARP cleavage was observed. In light of the
observed lack of effect of z-VAD-fmk treatment on DOX-induced
cell death this may suggest that a caspase-independent form of cell
death can be activated in parallel in these cells. Regardless of this,
monoHER very effectively suppressed caspase-9 activation and
PARP cleavage. We were not able to detect Bax or caspase-3
expression in NeRCaMs as the available antibodies did not cross-
react with the rat counterparts.
Next, the ovarian cancer cell lines were investigated. A2780 cells
(wild-type p53) showed clear DOX-induced p53 accumulation and
PARP cleavage that could be suppressed by monoHER (Figure 3C).
However, the mechanism of DOX-induced caspase activation in
A2780 cells was different from that in HUVECs, with no or hardly
any Bax, caspase-9 and -3 cleavage/activation, suggesting no
primary role for the mitochondrial pathway in mediating DOX-
dependent apoptosis in these cells. Nonetheless, A2780 cells
displayed clear PARP cleavage after DOX exposure. In contrast,
OVCAR-3 cells showed little or no evidence for DOX-induced p53,
Bax or caspase activation or PARP cleavage (Figure 3D). This was
not unexpected because these cells contain mutant p53 and show
resistance against apoptosis.
DISCUSSION
The antitumour effects of DOX results from preventing DNA
replication and repair leading to cell cycle arrest and apoptosis
(Capranico et al, 1990; Gewirtz, 1991; Binaschi et al, 1997).
Doxorubicin (DOX)-induced cardiotoxicity was related to the
activation of apoptosis in cardiomyocytes and endothelial cells
(Wu et al, 2002; Yamanaka et al, 2003; Spallarossa et al, 2004).
In these cells the main effects of DOX were mediated via the
production of ROS, known for its potent cell damaging effects.
Thus DOX-induced apoptosis, although via different routes, is a
common mechanism in normal and cancer cells.
Interestingly, the potent ROS scavenger monoHER, which is
presently in a clinical phase II study, showed a strong protection
against the cardiotoxic effects of DOX without modulating its
antitumour effects both in vivo and in vitro (van Acker et al, 1997;
van Acker et al, 2000; Abou El Hassan et al, 2003a,d). The anti-
apoptotic role played by monoHER and the contribution to its
selective protection is not studied yet. The present study was
therefore aimed to compare the protective effects of monoHER
against DOX-induced apoptosis in normal and cancer cells to
unravel the mechanism of its selective protection.
Doxorubicin (DOX) induced concentration-dependent apopto-
sis both in HUVECs and NeRCaMs, which is in line with an earlier
study (Wu et al, 2002). A2780 cells were also sensitive to induction
of apoptosis by DOX, whereas OVCAR-3 cells were highly
resistant. This resistance could be attributed to the presence of
mutant p53, but may also be caused by other yet unknown
apoptotic blockades. Employing the broad caspase inhibitor
z-VAD-fmk revealed that DOX triggered caspase-dependent
apoptosis in HUVECs and A2780 cells, and caspase-independent
cell death in NeRCaMs. Combination treatment with monoHER
was effective in suppressing both caspase-dependent (HUVECs
and A2780) and -independent apoptosis (NeRCaMs). Assessment
of the fold anti-apoptotic protection achieved showed that
HUVECs and NeRCaMs were stronger protected by monoHER
than A2780 cells. Examination of the molecular mechanisms that
underlie the protective effects of monoHER indicated that it can
strongly reduce the activation of DOX-induced p53 accumulation
in cardiomyocytes, endothelial cells and A2780 cells, which contain
wild-type p53 (Camarda et al, 2002), whereas as expected, no p53
response was detected in OVCAR-3 cells that express mutant p53.
It is conceivable that the radical scavenging properties of
monoHER cause the reduction of p53 accumulation, which is a
known sensor of ROS-dependent toxicity (Uberti et al, 1999),
leaving only topoisomerase 2-DNA damage as a trigger for p53
activation.
The suppressive effect of monoHER on the activation of
caspase-9 and -3 and the substrate PARP can also be explained
by the neutralisation of ROS-dependent triggers of caspase
activation. Evidence for mitochondria-dependent activation of
caspases was only obtained in HUVECs, in which DOX exposure
resulted in the occurrence of a shorter form of BAX, which was
suppressed by monoHER. This shorter form may be produced by
cleavage of full-length Bax or may represent an alternatively
spliced variant with mitochondria destabilising activity leading to
the apoptosome-dependent activation of caspase-9 and the
subsequent activation of apoptotic cell death (Youn et al, 2005).
In A2780 cells the mitochondrial pathway seemed to be less
involved in DOX-induced apoptosis because DOX did not show
clear changes in BAX or pro-caspase-9 or -3 levels. However, PARP
cleavage was clearly evident in A2780 cells and together with the
fact that zVAD-fmk strongly suppressed DOX-induced apoptosis,
we postulate that other yet unconfirmed mechanisms of caspase-
dependent apoptosis are activated, such as the extrinsic pathway
and caspase-8. The opposite holds true for NeRCaMs in which
DOX activated p53 as shown by caspase-9 and PARP cleavage,
whereas the addition of z-VAD-fmk only partially suppressed
apoptosis indicative of caspase-independent cell death. In
NeRCaMs, the observed caspase-9 activation seems to be merely
a co-phenomenon of DOX-induced apoptosis. In line with that,
Youn et al (2005) reported that DOX-induced death of the rat
cardiac muscle cell line H9c2 was associated with p53 upregulation
and caspase-independency. Altogether, this indicates the involve-
ment of caspase-independent apoptotic routes in mediating death
in cardiac myocytes by DOX. This cannot be generalised because
in other cell types (in our study and in previous reports) caspases
seem to play a role in DOX-induced cell death (Nakamura et al,
2000; Grassilli et al, 2004; Kalivendi et al, 2005). Together this
supports the idea that more than one mechanism can mediate
programmed cell death, which depends on both the death stimulus
provided and the cell type studied (Bro ¨ker et al, 2005). MonoHER
appears to protect against these diverse DOX-induced cell death
signals, possibly because of the ability of monoHER to neutralise
ROS. OVCAR-3 cells were different in their response to DOX
compared to the other cell types. They showed hardly any
apoptosis within the concentration range of 0.5–10mM, which is
comparable to clinically achieved concentrations of DOX (0.3–
5mM) (Gerwitz, 1999). MonoHER did cause cell cycle delay in G2/M
in these cells but did not affect the small amount of DOX-induced
cell death.
The finding that monoHER not only suppresses apoptosis in
endothelial cells and cardiomyocytes at clinically relevant con-
centrations of DOX, but also in ovarian cancer cells raises the
question whether monoHER may reduce the antitumour effects of
DOX in the clinic. It should be noted that in the present study a
concentration of 1mM monoHER is used. This concentration is
about threefold or sevenfold higher than the maximal peak plasma
concentrations of monoHER found in the clinic (360mM) during
the phase I study (Willems et al, 2006) or in mice (131mM) under
protecting conditions (Abou El Hassan et al, 2003c). Thus,
monoHER provides a potent protective effect against various
routes of doxorubicin-induced cell death allowing an efficient
protection of heart and endothelial cells reported previously as
major targets in doxorubicin-induced cardiotoxicity. Importantly,
the present study addresses the necessity not to raise the dose of
monoHER above the presently used 1500mgm
2 to avoid
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the antitumour activity of DOX.
Finally, we postulate that the tendency of monoHER to protect
normal cells more than cancer cells may be attributed to the
inherent proliferation capacity of cancer cells, even in confluent
cultures as used in this study where the growth of tumour cells is
less affected by contact inhibition. It can be envisioned that in
slow- or non-proliferating cells, such as normal cardiomyocytes
and endothelial cells, monoHER predominantly acts against the
apoptotic effects of DOX and consequently offers more protection.
This is supported by our results showing restricted monoHER
protection of confluent but not proliferating endothelial cells after
DOX treatment in vitro (Abou El Hassan et al, 2003d). On the
other hand, the different effects of monoHER in terms of apoptosis
suppression may reflect the activity of the intrinsic ROS defence
systems present in cells, which may also be associated with
different mechanisms of cell death activation. In this respect,
multiple antioxidant defence systems/enzymes (for example,
glutathione, thioredoxin and SOD) are active to varying degrees
in different cell types thereby forming complex ROS-neutralising
networks that are related to apoptosis (Haddad, 2004). In addition,
cardiomyocytes were reported to have intrinsically low levels of
antioxidant enzymes that may explain the potent protective
function of monoHER in these cells (Hrdina et al, 2000). Also
high activity of the MRP1/ GS-X pump in these cells was reported
(Krause et al, 2007), which may export DOX as glutathione-S-
conjugate out of the cells, thereby modifying its cytotoxic effects.
However, previously we found that monoHER did not affect DOX
levels in cardiac cells in mice or influence the biodistribution of
DOX (Abou El Hassan et al, 2003b). Thus, although the level of
ROS defense is likely to at least partially determine the protective
effect of monoHER in cells, the high complexity of these defense
mechanisms makes it difficult to discriminate between their
relative contribution to monoHER protection and the relevance
for counteracting DOX-induced apoptosis, and will require a
systematic, more detailed analysis.
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